Press Release

Boston, Mass., October 16, 2019  – Pyxis Oncology, an immuno-oncology company focused on developing a new family of antibody-based immunotherapies derived from novel insights into the biology of the tumor microenvironment, today announced the appointment of Ronald Herbst, PhD, as Chief Scientific Officer effective October 15, 2019. Dr. Herbst joins Pyxis from MedImmune, where he was […]

Building on New Insights in Tumor Biology Discovered by Award-winning Cancer Researcher Thomas Gajewski, MD, PhD USD 22 Million Series A to Fund Pipeline of Antibodies Focused on Novel Immuno-oncology Targets Leverkusen, Germany and Boston, Mass., July 17, 2019 – Pyxis Oncology (“Pyxis”), a newly formed immuno-oncology company, launched today with a focus on developing a